TrialClinical cancer research : an official journal of the American Association for Cancer Research2026
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).
Daniel J Hodson et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.